Effects of Nicotine Dependence on Multidimensional Health Outcomes

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorIzmir Democracy University

About this trial

Nicotine, a major toxic component of cigarette smoke, together with carbon monoxide (CO), constitutes a significant environmental exposure with systemic effects. Beyond its addictive potential, chronic nicotine exposure may induce inflammation, oxidative stress, tissue hypoxia, and autonomic imbalance, potentially impairing respiratory muscle strength, functional capacity, and overall physical performance. Additionally, nicotine dependence has been associated with sleep disturbances, cognitive dysfunction, altered pain perception, and reduced quality of life.

Although previous studies have examined individual effects of smoking on specific health outcomes, research addressing these multidimensional impacts within a comprehensive framework remains limited. Therefore, this study aims to investigate the relationship between nicotine dependence level and respiratory muscle strength, functional capacity, cognitive functions, pain, quality of life, physical activity level, and sleep quality, in order to provide a more holistic understanding of the clinical consequences of nicotine dependence.

Eligibility criteria

Qualifiers

Regular cigarette use for at least the past 6 months

No history of respiratory, cardiovascular, or neurological/psychiatric disease

No recent history of surgery or trauma that could affect respiratory muscles

No current acute infection (especially upper or lower respiratory tract infections)

Disqualifiers

Presence of chronic respiratory diseases such as COPD or

History of cardiovascular disease

Diagnosed neurological or psychiatric disorders

history of surgery or trauma affecting the respiratory muscles within the last 3 months

Trial design

Treatments tested in this trial

  • Comprehensive Clinical Assessment

Treatment groups

212 Participants
are divided into 1 treatment group

Sponsors and collaborators